Weber J N, Clapham P R, Weiss R A, Parker D, Roberts C, Duncan J, Weller I, Carne C, Tedder R S, Pinching A J
Lancet. 1987 Jan 17;1(8525):119-22. doi: 10.1016/s0140-6736(87)91964-7.
Sequential sera from 48 subjects infected with human immunodeficiency virus type I (HIV-I) were examined over 36 months for the presence of neutralising antibodies, and for specific anti-gag (p24) and anti-env (gp41) antibodies to HIV-I. Results were interpreted in terms of clinical outcome during the period 1982/3 to 1985/6. HIV-I-infected subjects who remained symptom-free, by comparison with those who manifested AIDS or AIDS-related complex (ARC), had a significantly higher titre of anti-p24 antibodies throughout the 3 years, as measured by competitive enzyme-linked immunosorbent assay and radioimmunoprecipitation. The symptomless subjects also showed a trend towards an increasing neutralising antibody titre with time. There was no relation between anti-gp41 titre and clinical outcome, nor an independent relation between anti-p24 and neutralising titre. A lower or falling titre of anti-p24 antibody was associated significantly with clinical progression, up to 27 months before development of AIDS/ARC.
对48名感染I型人类免疫缺陷病毒（HIV-I）的受试者的系列血清进行了为期36个月的检测，以检查其中是否存在中和抗体，以及是否存在针对HIV-I的特异性抗gag（p24）和抗env（gp41）抗体。根据1982/3至1985/6期间的临床结果对结果进行了解释。与出现艾滋病或艾滋病相关综合征（ARC）的受试者相比，在整个3年期间，无症状的HIV-I感染受试者通过竞争性酶联免疫吸附测定和放射免疫沉淀法测得的抗p24抗体滴度显著更高。无症状受试者的中和抗体滴度也呈现出随时间增加的趋势。抗gp41滴度与临床结果之间没有关系，抗p24滴度与中和滴度之间也没有独立关系。抗p24抗体滴度降低或下降与临床进展显著相关，这种情况在发展为艾滋病/ARC前27个月就已出现。
